Lee Pharmaceuticals (LPHM) News Today Add Compare Share Share Headlines Stock AnalysisChartSEC FilingsBuy This Stock LPHM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific SessionsJune 21, 2025 | prnewswire.comGan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or ObesityMarch 10, 2025 | prnewswire.comGan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two WeeksNovember 12, 2024 | prnewswire.comLongboard Pharmaceuticals (LBPH) Receives a Hold from Truist FinancialNovember 11, 2024 | markets.businessinsider.comObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese AdultsNovember 11, 2024 | prnewswire.comGan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical StudiesOctober 15, 2024 | prnewswire.comAssessing Longboard Pharmaceuticals’ Acquisition: Undervalued Potential Amidst Industry InterestOctober 14, 2024 | markets.businessinsider.comGan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)September 14, 2024 | prnewswire.comFranklin Regional graduate Spencer Lee soars to semi-finals in Paris Olympics 57kg FreeStyleAugust 9, 2024 | msn.comGymnastics-Lee credits doctors and team for lifting her to Paris Olympic gloryAugust 6, 2024 | reuters.comGymnastics-Lee overcomes illness, criticism to return to Olympic podiumAugust 1, 2024 | reuters.comGan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical TrialJuly 22, 2024 | prnewswire.comGan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific SessionsJune 22, 2024 | prnewswire.comGan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific SessionsJune 17, 2024 | prnewswire.comSingapore to inaugurate new PM as Lee makes way after 20 years in chargeMay 14, 2024 | msn.comSingapore PM Lee to hand power to successor Wong on May 15April 15, 2024 | msn.com5th Kansas City Chiefs fan at party where 3 friends were later found frozen to death ID’d: reportFebruary 10, 2024 | nypost.comNPatrick Lee | ReutersFebruary 7, 2024 | reuters.comGan & Lee Pharmaceuticals Co. Ltd. AJanuary 3, 2024 | wsj.com3x NCAA Champion Spencer Lee Makes an Audacious Statement Regarding 1960’s Olympic MedalistJanuary 2, 2024 | msn.comLee HockstaderNovember 21, 2023 | washingtonpost.comLee’s Pharmaceutical Holdings Ltd (0950)November 4, 2023 | investing.comLee's Pharmaceutical Holdings Ltd.November 3, 2023 | wsj.comWendy LeeOctober 26, 2023 | latimes.comGan & Lee Pharmaceuticals Co Ltd (603087)October 10, 2023 | investing.comMichael LeeMay 15, 2023 | washingtonpost.com Get Lee Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LPHM and its competitors with MarketBeat's FREE daily newsletter. Email Address LPHM Media Mentions By Week LPHM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LPHM News Sentiment▼0.000.78▲Average Consumer Staples News Sentiment LPHM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LPHM Articles This Week▼00▲LPHM Articles Average Week Get Lee Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LPHM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GRNQ News CLIK News HTCR News TNMG News VS News EPWK News SKYQ News SUGP News GLXG News KRKR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:LPHM) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lee Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lee Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
